Power Wheelchair Group 3 denied as experimental or investigational by Humana?

Humana's specific coverage criteria for power wheelchair group3 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny a Group 3 Power Wheelchair as Experimental — and Why That Is Often Wrong

Denying a Group 3 complex rehab power wheelchair as "experimental" or "investigational" is among the less common but most aggressive DME denials. It typically arises when Humana's coverage policy has not been updated to reflect current clinical standards for complex rehab technology, when the specific Group 3 feature set or configuration requested is newer, or when the supporting clinical documentation is insufficient for Humana to map the request to an established indication. In some cases it reflects a coding or documentation issue rather than a genuine experimental determination.

## Why This Denial Is Appealable

Group 3 power wheelchairs are not experimental. They are classified and reimbursed by CMS under the Medicare DME benefit, and that classification is grounded in extensive clinical use and manufacturer clearance processes. An "experimental" denial that ignores the established clinical literature, the CMS classification framework, and the relevant clinical guidelines from major rehabilitation medicine and physical therapy organizations is highly vulnerable on appeal — particularly at the external review stage where an IRO applies generally accepted clinical standards, not just Humana's internal policy.

## Federal Appeal Framework

• Internal appeal: Challenge the experimental determination head-on at Level 1, citing Humana's own obligation to align with generally accepted clinical standards. File within the EOB window; standard pre-service turnaround is 30 days, expedited is 72 hours.
• External review (ACA §2719): Experimental/investigational denials are among the most commonly overturned at external review, because IROs apply accepted clinical standards rather than insurer-specific coverage criteria. File for external review promptly — you have approximately four months from the final internal denial.
• ERISA §503: Employer-plan members are entitled to full-and-fair review and the complete claim file. The claim file will reveal which clinical evidence Humana relied upon — and often what it ignored.

## Documentation to Gather

• Clinical guidelines: A letter from your prescribing physician or physiatrist referencing the applicable rehabilitation medicine, physical therapy, and complex rehab technology clinical guidelines from the relevant professional organizations — without citing specific numbers, but confirming the clinical standard supports the prescription.
• Manufacturer clearance documentation: Group 3 device manufacturers can provide documentation of FDA clearance pathways and published clinical evidence supporting the device's safety and efficacy for your indication.
• Functional assessment: An evaluation documenting your functional profile and confirming that the requested device configuration is the recognized standard of care for that profile.
• Humana's coverage policy: Obtain the current version and identify what Humana's own "experimental" definition requires — then show the device does not meet that definition.

## Criteria-Mapping Structure

Draft a side-by-side table: Humana's stated basis for the experimental determination on the left; the specific rebuttal evidence (clinical guideline organization, CMS classification, prescriber opinion, device clearance) on the right. External reviewers respond well to organized, direct rebuttals of each stated rationale.